Pancreatic Cancer Therapeutics Market by Type (Endocrine Pancreatic Cancer, Exocrine Pancreatic Cancer), Product (Chemotherapy, Gene Therapy, Immunotherapy), End-Use - Global Forecast 2024-2030
Description
Pancreatic Cancer Therapeutics Market by Type (Endocrine Pancreatic Cancer, Exocrine Pancreatic Cancer), Product (Chemotherapy, Gene Therapy, Immunotherapy), End-Use - Global Forecast 2024-2030
The Pancreatic Cancer Therapeutics Market size was estimated at USD 4.67 billion in 2023 and expected to reach USD 5.14 billion in 2024, at a CAGR 9.95% to reach USD 9.09 billion by 2030.
Pancreatic cancer therapeutics encompass a variety of treatment modalities used to manage and combat pancreatic cancer, known for its aggressive nature and challenging prognosis. The therapeutic landscape for this malignancy includes surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, and supportive care measures that aim to relieve symptoms and improve the quality of life for patients. The need for pancreatic cancer therapeutics is driven by the increasing prevalence of the disease, attributed to factors such as aging populations, lifestyle-related risk factors, and genetic predispositions. Additionally, supportive government policies to expand access to affordable pancreatic cancer treatment have extended the scope and reach of the therapeutic options for patients. However, the complex reimbursement landscape and the inability of clinical trials to provide beneficial and credible results pose concerns about the accuracy and efficacy of the therapies. Moreover, there has been some significant progress in understanding the biology of the disease, resulting in the development of targeted therapeutics and personalized medicine approaches. These treatments are designed to interfere with specific pathways or mechanisms that promote the growth and spread of pancreatic cancer cells.
Regional Insights
The Americas region, particularly the United States and Canada, is characterized by the presence of a robust clinical pipeline, high healthcare expenditure, and several major pharmaceutical companies. Food and Drug Administration (FDA) has approved designations such as Fast Track, Breakthrough Therapy, and Orphan Drug to several pancreatic cancer drugs, which accelerates the regulatory approval process. European nations such as Germany, France, and the United Kingdom are characterized by the presence of heightened healthcare spending, advanced healthcare facilities, and favorable reimbursement policies. The European Medicines Agency (EMA) plays a pivotal role in endorsing new therapeutic options, positively impacting market growth. Strong research collaborations between private and public entities drive innovation in cancer therapeutic research. In APAC countries such as China, Japan, India, and South Korea, there is a growing patient population and increasing awareness regarding cancer diseases, driving the need for therapeutic options. The increase in local generic drug production in countries such as India contributes to regional market dynamics.
Market Insights
- Market Dynamics
The market dynamics represent an ever-changing landscape of the Pancreatic Cancer Therapeutics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.- Market Drivers
- Rising prevalence of pancreatic cancer cases across the world
- Government initiatives to expand access to pancreatic cancer treatment options
- Market Restraints
- Adverse drug recalls and difficulty in availing reimbursement options
- Market Opportunities
- Research initiatives and advancements to improve the efficacy of pancreatic cancer therapeutics
- Approvals for pancreatic cancer therapy and orphan drug approvals for cancer treatment
- Market Challenges
- Limitations and complications of pancreatic cancer treatment options and lack of trained medical professionals
- Market Segmentation Analysis
- Type: Need for rapid deployment of therapeutic options due to fast progression of exocrine pancreatic cancer
- Product: Expanding number of approvals for chemotherapy treatment options
- End-Use: Expanding presence of collaborations and R&D initiatives in research institutes for pancreatic cancer treatment
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Pancreatic Cancer Therapeutics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Pancreatic Cancer Therapeutics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments- Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients
Trishula Therapeutics, Inc., a clinical-stage biotechnology company, revealed the initiation of a randomized Phase 2 trial to assess the efficacy and safety of TTX-030, an anti-CD39 antibody, for the treatment of metastatic pancreatic ductal adenocarcinoma patients. This trial is expected to evaluate the combination of TTX-030 with chemotherapy, either with or without budigalimab (an investigational anti-PD-1 antibody), as a first-line treatment option. The study aims to enroll approximately 180 patients worldwide and will primarily focus on assessing progression-free survival in a biomarker-enriched population.
Lisata Receives Orphan Drug Designation For Pancreatic Cancer Therapy
Lisata Therapeutics was granted orphan drug designation from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products for LSTA1, an investigational drug specifically designed to treat pancreatic cancer. LSTA1 aims to activate a novel uptake pathway, allowing co-administered or tethered anti-cancer drugs to penetrate solid tumors effectively. Non-clinical data collected by Lisata and its partners demonstrates the enhanced delivery of established and emerging cancer treatments, including immunotherapy, chemotherapy, and RNA-based therapies.
PanCAN Announces New & Advanced Research Investment
PanCAN committed an unprecedented USD 34 million to its research endeavors, and the funding facilitated the awarding of nine coveted research grants. The research grants emphasize the organization's role as a driving force for progress within the pancreatic cancer sphere, nurturing brilliant scientists proposing cutting-edge research and fostering mentorship for upcoming talent. This impressive array of grants underscores PanCAN's commitment to driving critical advanements and supporting innovative research to defeat pancreatic cancer.
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Pancreatic Cancer Therapeutics Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Pancreatic Cancer Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Amgen Inc., Ascentage Pharma Group, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Carl Zeiss AG, Carrick Therapeutics Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Faeth Therapeutics, Inc., FUJIFILM Holdings Corporation, GE HealthCare Technologies, Inc., GenesisCare, GlaxoSmithKline PLC, Hetero Healthcare Limited, ImmunityBio, Inc., Innovent Biologics Inc., Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Mitsubishi Heavy Industries, Ltd., NGM Biopharmaceuticals, Inc., NovalGen, Novartis AG, PanTher Therapeutics, Inc., Pfizer, Inc., RenovoRx, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Zentalis Pharmaceuticals, Inc..
Market Segmentation & Coverage
This research report categorizes the Pancreatic Cancer Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:- Type
- Endocrine Pancreatic Cancer
- Exocrine Pancreatic Cancer
- Product
- Chemotherapy
- Gene Therapy
- Immunotherapy
- Radiation Therapy
- Surgery
- Targeted Therapy
- End-Use
- Cancer Centers/Clinics
- Hospitals
- Research Institutes
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year
- Americas
- Market Drivers
Table of Contents
194 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising prevalence of pancreatic cancer cases across the world
- 5.1.1.2. Government initiatives to expand access to pancreatic cancer treatment options
- 5.1.2. Restraints
- 5.1.2.1. Adverse drug recalls and difficulty in availing reimbursement options
- 5.1.3. Opportunities
- 5.1.3.1. Research initiatives and advancements to improve the efficacy of pancreatic cancer therapeutics
- 5.1.3.2. Approvals for pancreatic cancer therapy and orphan drug approvals for cancer treatment
- 5.1.4. Challenges
- 5.1.4.1. Limitations and complications of pancreatic cancer treatment options and lack of trained medical professionals
- 5.2. Market Segmentation Analysis
- 5.2.1. Type: Need for rapid deployment of therapeutic options due to fast progression of exocrine pancreatic cancer
- 5.2.2. Product: Expanding number of approvals for chemotherapy treatment options
- 5.2.3. End-Use: Expanding presence of collaborations and R&D initiatives in research institutes for pancreatic cancer treatment
- 5.3. Market Trend Analysis
- 5.3.1. Advancements in pancreatic cancer therapeutics in Americas region due to strong presence of key players and supportive regulatory landscape
- 5.3.2. Collaborative R&D activities by cancer research organization and improved support for clinical trials of novel therapies to elevate the advancements in pancreatic cancer therapeutics in the Asia-Pacific
- 5.3.3. Concerted efforts of researchers, funding agencies, and regulatory bodies catalyzing to delivering novel pancreatic cancer therapeutic solutions across EMEA
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework Analysis
- 6. Pancreatic Cancer Therapeutics Market, by Type
- 6.1. Introduction
- 6.2. Endocrine Pancreatic Cancer
- 6.3. Exocrine Pancreatic Cancer
- 7. Pancreatic Cancer Therapeutics Market, by Product
- 7.1. Introduction
- 7.2. Chemotherapy
- 7.3. Gene Therapy
- 7.4. Immunotherapy
- 7.5. Radiation Therapy
- 7.6. Surgery
- 7.7. Targeted Therapy
- 8. Pancreatic Cancer Therapeutics Market, by End-Use
- 8.1. Introduction
- 8.2. Cancer Centers/Clinics
- 8.3. Hospitals
- 8.4. Research Institutes
- 9. Americas Pancreatic Cancer Therapeutics Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Pancreatic Cancer Therapeutics Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa Pancreatic Cancer Therapeutics Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. Market Share Analysis, 2023
- 12.2. FPNV Positioning Matrix, 2023
- 12.3. Competitive Scenario Analysis
- 12.3.1. Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients
- 12.3.2. Lisata Receives Orphan Drug Designation For Pancreatic Cancer Therapy
- 12.3.3. PanCAN Announces New & Advanced Research Investment
- 12.3.4. Prestige Biopharma and Imagion Biosystems Sign Partnership Agreement to Develop Early Pancreatic Cancer Diagnosis Platform
- 12.3.5. TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation
- 12.3.6. Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics
- 12.3.7. Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy
- 12.3.8. FDA Grants Breakthrough Therapy Designation to Zenocutuzumab for NRG1+ Pancreatic Cancer
- 12.3.9. FDA Clears TME Pharma’s IND for Pancreatic Cancer Therapy Trial
- 12.3.10. GenesisCare Launches ViewRay MRIdian MRI-Guided Radiation Therapy System at Lee Health Regional Cancer Center
- 12.3.11. USD 3 Million National Grant to Fund Pancreatic Cancer Study
- 12.3.12. Leap Therapeutics Acquires Flame Biosciences
- 12.3.13. Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
- 12.3.14. Faeth Therapeutics Raises USD 47 million to Advance Clinical Trials for Cancer
- 12.3.15. AstraZeneca-Merck's Lynparza Wins EU Approval for Pancreatic Cancer
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.2. Key Product Portfolio
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
